tradingkey.logo

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma To Support Commercialization Of VK2735

ReutersMar 11, 2025 11:05 AM

- Viking Therapeutics Inc VKTX.O:

  • VIKING THERAPEUTICS SIGNS BROAD MANUFACTURING AGREEMENT WITH CORDENPHARMA TO SUPPORT COMMERCIALIZATION OF VK2735

  • VIKING THERAPEUTICS INC - VIKING TO MAKE PREPAYMENTS TOTALING $150 MILLION BETWEEN 2025-2028

  • VIKING THERAPEUTICS INC - CORDENPHARMA WILL PROVIDE FILL/FINISH CAPACITY FOR BOTH INJECTABLE AND ORAL FORMULATIONS OF VK2735

  • VIKING THERAPEUTICS INC - PLANS TO INITIATE PHASE 3 DEVELOPMENT WITH SUBCUTANEOUS FORMULATION OF VK2735 IN Q2 OF 2025.

  • VIKING THERAPEUTICS INC - AGREEMENT PROVIDES ANNUAL CAPACITY OF OVER ONE BILLION ORAL VK2735 TABLETS.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI